No Data
No Data
Lucid Diagnostics Announces Positive Data From Its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing in a Screening Population
Express News | PAVmed's Veris Health Subsidiary Launches Pilot Program With Ohio State University Comprehensive Cancer Center; First Patients Enrolled In Veris Cancer Care Platform
Express News | PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program With the Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Express News | PAVmed Inc : Ascendiant Capital Markets Cuts Target Price to $22 From $26
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and PAVmed (PAVM)
Analysts' Opinions Are Mixed on These Healthcare Stocks: HUTCHMED (HCM) and PAVmed (PAVM)
No Data